Compare ARCO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCO | ZLAB |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | Uruguay | China |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2011 | 2017 |
| Metric | ARCO | ZLAB |
|---|---|---|
| Price | $8.52 | $20.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $8.60 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 1.5M | 874.3K |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $12.56 | $9.75 |
| Revenue Next Year | $3.48 | $26.03 |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $6.51 | $15.96 |
| 52 Week High | $9.75 | $41.20 |
| Indicator | ARCO | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 68.60 |
| Support Level | $8.51 | $16.84 |
| Resistance Level | $9.01 | $21.33 |
| Average True Range (ATR) | 0.22 | 0.75 |
| MACD | 0.03 | 0.29 |
| Stochastic Oscillator | 84.92 | 93.73 |
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Its menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others. It generates maximum revenue from Brazil.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.